EP Patent

EP2559435A1 — Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke

Assigned to UCB Pharma GmbH · Expires 2013-02-20 · 13y expired

What this patent protects

The present invention relates to the use of rotigotine for the effective treatment of a condition or disorder selected from neglect, stroke, conditions associated with stroke and/or following stroke. The invention also relates to a rotigotine-containing pharmaceutical composition…

USPTO Abstract

The present invention relates to the use of rotigotine for the effective treatment of a condition or disorder selected from neglect, stroke, conditions associated with stroke and/or following stroke. The invention also relates to a rotigotine-containing pharmaceutical composition, like a transepicutaneous. pharmaceutical composition especially in the form of a Transdermal Therapeutic System (TTS).

Drugs covered by this patent

Patent Metadata

Patent number
EP2559435A1
Jurisdiction
EP
Classification
—
Expires
2013-02-20
Drug substance claim
No
Drug product claim
No
Assignee
UCB Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.